Ku saabsan-kansarka / daaweynta / tijaabooyinka-kiliinikada / cudurka / intraocular-melanoma / daaweynta

Daaweynta Tijaabooyinka Caafimaadka ee Intraocular Melanoma

Tijaabooyinka caafimaad waa daraasado cilmi baaris ah oo dadka ku lug leh. Tijaabooyinka bukaan-eegtada ee liiskan waxaa loogu talagalay daaweynta melanoma ee intraocular. Dhammaan tijaabooyinka ku jira liiska waxaa taageera NCI.

Macluumaadka aasaasiga ah ee NCI ee ku saabsan tijaabooyinka bukaan socodka wuxuu sharxayaa noocyada iyo wejiyada tijaabooyinka iyo sida loo fuliyo. Tijaabooyinka caafimaad waxay eegaan habab cusub oo looga hortago, lagu ogaado, ama lagu daweeyo cudur. Waxaa laga yaabaa inaad rabto inaad ka fikirto kaqeybqaadashada tijaabada caafimaadka. La hadal dhakhtarkaaga si uu kaaga caawiyo go aansashada haddii mid kugu habboon yahay.

Tijaabada 1-25 ee 25

Badbaadada iyo Waxtarka ee IMCgp100 oo kahortaga Xulashada Baarayaasha ee Advanced Uveal Melanoma

Si loo qiimeeyo badbaadada guud ee HLA-A * 0201 bukaanada qaangaarka ah ee qaangaarka ah ee aan horay loo daaweyn UM ee qaata IMCgp100 marka la barbar dhigo Xulashada Baaraha dacarbazine, ipilimumab, ama pembrolizumab.

Goobta: 19 goobood

Daraasad ku saabsan XmAb®22841 Monotherapy & Isku-darka w / Pembrolizumab ee Mawduucyada w / Burooyinka Soodhawrka Sare ee Xullan

Tani waa Wajiga 1, qaadasho badan, daraasad sare uqaadis ah iyo daraasad ballaadhin loogu talagalay in lagu qeexo qiyaasta ugu badan ee loo dulqaadan karo iyo / ama qiyaasta lagu taliyey ee daaweynta montrapia ee XmAb22841 laguna daro pembrolizumab; si loo qiimeeyo amniga, dulqaadka, daawooyinka dawooyinka, difaaca jirka, iyo waxqabadka ka hortagga burooyinka ee XmAb22841 monotherapy iyo isku darka pembrolizumab maadooyinka leh burooyin adag oo la xushay.

Goobta: 10 goobood

Daraasadda RP1 Monotherapy iyo RP1 ee Isku-darka Nivolumab

RPL-001-16 waa Wajiga 1/2, calaamadda furan, xaddiga kordhinta iyo ballaarinta daraasadda bukaan-socodka ee RP1 oo keliya iyo isku-darka nivolumab ee maaddooyinka qaangaarka ah ee leh burooyin heer sare ah iyo / ama diidan, si loo go'aamiyo qiyaasta ugu badan ee loo dulqaadan karo (MTD) iyo lagula taliyay qiyaasta Wajiga 2 (RP2D), iyo sidoo kale in la qiimeeyo waxtarka hordhaca ah.

Goobta: 6 goobood

Barashada Mawduucyada leh Melanoma Hoose ee Choroidal Yar

Ujeeddada koowaad ayaa ah in la qiimeeyo amniga, difaaca jirka iyo waxtarka mid ka mid ah seddexda heer qiyaaso isla markaana lagu celceliyo qiyaasta daawada ee loo yaqaan 'Light-activated AU-011' iyo hal ama laba codsi oo laser ah oo lagu daaweynayo maadooyinka leh melanoma choroidal ee aasaasiga ah.

Goobta: 4 goobood

Daraasada IDE196 ee Bukaannada qaba Burooyinka Adag ee Sunta GNAQ / 11 Isbadalo ama Fusyo PRKC

Tani waa Wajiga 1/2, xarumo fara badan, daraasad dambiil furan oo loogu talagalay in lagu qiimeeyo amniga iyo ka hortagga burooyinka ee IDE196 ee bukaanada qaba burooyinka adag ee gaboodka GNAQ ama GNA11 (GNAQ / 11) ama isku-darka PRKC, oo ay ku jiraan metastatic uveal melanoma (MUM), melanoma cutaneous, kansarka mindhicirka, iyo burooyinka kale ee adag. Marxaladda 1 (kordhinta qiyaasta) ayaa qiimeyn doonta amniga, dulqaadka iyo farmasokokinetikada ee IDE196 iyadoo loo marayo nidaamka kor u qaadista qiyaasta caadiga ah iyo go'aaminta qiyaasta Wajiga 2 ee lagu taliyay. Waxqabadyada nabdoonaanta iyo ka hortagga burooyinka ayaa lagu qiimeyn doonaa Qeybta 2 (kordhinta qiyaasta) ee daraasadda.

Goobta: 4 goobood

Selumetinib Sulfate ee lagu daaweynayo bukaanada qaba Uveal Melanoma ama GNAQ / GNA11 Melanoma Isbedeshay oo Metastatic ah ama aan lagu saari karin qalliin

Tijaabadan wejiga Ib waxay tijaabineysaa waxyeelada iyo qiyaasta ugu wanaagsan ee selumetinib sulfate ee lagu daaweynayo bukaanada qaba uveal melanoma ama GNAQ / GNA11 melanoma is bedeshay oo ku faaftay goobta aasaasiga ah ilaa meelo kale oo jirka ah ama laguma saari karo qalliin. Selumetinib sulfate waxay joojin kartaa koritaanka unugyada burooyinka iyagoo xayiraya qaar ka mid ah enzymes-ka loo baahan yahay koritaanka unugyada.

Goobta: 3 goobood

Virus-ka wax laga badalay VSV-IFNbetaTYRP1 ee Daaweynta Bukaanka Heerka III-IV Melanoma

Tijaabadan wejigan 1aad waxay daraasad ku samaysaa dhibaatooyinka soo raaca iyo qiyaasta ugu wanaagsan ee fayraska la beddelay ee loo yaqaan VSV-IFNbetaTYRP1 ee lagu daaweynayo bukaannada qaba heerka III-IV melanoma. Fayraska loo yaqaan 'vesicular stomatitis virus' (VSV) waxaa loo badalay in lagu daro labo hiddo-wade oo dheeri ah: human interferon beta (hIFNbeta), oo ka ilaalin kara unugyada caafimaadka qaba ee caadiga ah inay ku dhacaan cudurka, iyo TYRP1, oo inta badan lagu muujiyo melanocytes (unug maqaar gaar ah leh waxay soo saartaa maqaarka ilaaliya maqaarka madow ee melanin) iyo unugyada burooyinka melanoma, waxayna kicin kartaa jawaab celin xoog leh oo difaac ah si loo dilo unugyada burooyinka melanoma.

Goobta: 2 goobood

Daraasad ku saabsan PLX2853 ee Xanuunada Hormarinta.

Ujeedada daraasaddan cilmibaadhista ayaa ah in lagu qiimeeyo nabadgelyada, dawooyinka dawooyinka, farmasiga iyo firfircoonida horudhaca ah ee dawada baaritaanka ee PLX2853 maadooyinka qaba astaamaha daran.

Goobta: 2 goobood

Yttrium90, Ipilimumab, & Nivolumab oo loogu talagalay Uveal Melanoma oo leh Beerta metastases

Warbixinnada ilaa maanta waxay muujinayaan waxtarka xaddidan ee difaaca jirka ee 'uveal melanoma'. Tijaabooyinkii ugu dambeeyay iyo caddaynta caafimaad waxay soo jeedinayaan isdhexgalka u dhexeeya daaweynta shucaaca iyo difaaca jirka. Baarayaasha waxay baari doonaan iswaafajintaan daraasad suurtagal ah oo ku saabsan 26 bukaan oo qaba uveal melanoma iyo metastases hepatitis kuwaas oo heli doona shucaaca SirSpheres Yttrium-90 xulashada cagaarshowga gudaha oo ay ku xigto tallaalka daaweynta iskudhafka ipilimumab iyo nivolumab.

Goobta: 2 goobood

Pegargiminase, Nivolumab iyo Ipilimumab ee Daaweynta Bukaannada leh Uveal Melanoma Heer Sare ah ama aan laga bogsan karin

Tijaabadani wajiga 1aad waxay tijaabineysaa waxyeelada pegargiminase, nivolumab iyo ipilimumab ee daaweynta bukaanada qaba uveal melanoma oo ku faaftay meelo kale oo jirka ah (horumarsan) ama aan qalliin looga saari karin (aan la xakamayn karin). Pegargiminase wuxuu joojin karaa koritaanka unugyada burooyinka isagoo xannibaya qaar ka mid ah enzymes-ka loo baahan yahay koritaanka unugyada. Immunotherapy oo leh unugyada unugyada monoclonal, sida nivolumab iyo ipilimumab, ayaa ka caawin kara habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin ku yeelan karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Bixinta pegargiminase, nivolumab iyo ipilimumab ayaa laga yaabaa inay ka fiicnaadaan marka loo barbar dhigo tallaalka difaaca jirka oo keliya.

Goobta: Xarunta Kansarka ee 'Sloan Kettering Cancer Center', New York, New York

Daaweynta shucaaca jirka ee firfircoonida iyo xayeysiinta daaweynta bukaanka Uveal Melanoma

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa sida wanaagsan ee daaweynta shucaaca jirka ee loo yaqaan 'stereotactic therapy radiation and aflibercept work' ee daaweynta bukaanada qaba uveal melanoma. Daaweynta shucaaca jirka ee loo yaqaan 'Stereotactic radiation radiation' waxay isticmaashaa qalab gaar ah si loo meeleeyo bukaanka loona gaarsiiyo shucaaca burooyinka leh saxsanaanta sare. Qaabkani wuxuu dili karaa unugyada burooyinka iyadoo qiyaaso yar la qaato mudo gaaban isla markaana waxyeelo yar u geyso unugyada caadiga ah. Aflibercept waxay joojin kartaa koritaanka unugyada burooyinka iyadoo xannibaysa qaar ka mid ah enzymes-ka loo baahan yahay koritaanka unugyada. Bixinta daaweynta shucaaca jirka ee qalafsanaanta oo ay ku xigto aflibercept ayaa si fiican uga shaqeyn karta daaweynta bukaanada qaba uveal melanoma.

Goobta: Isbitaalka Jaamacadda Thomas Jefferson, Philadelphia, Pennsylvania

Daraasad ku saabsan Amniga iyo dulqaadashada ee INCAGN02390 ee Xullo Xun oo Horumar leh

Ujeedada daraasaddan ayaa ah in la go'aamiyo nabadgelyada, dulqaadka, iyo waxtarka hordhaca ah ee INCAGN02390 ee kaqeybgalayaasha leh xulashooyinka xunxun ee horumarsan.

Goobta: Xarunta Caafimaadka ee Jaamacadda Hackensack, Hackensack, New Jersey

Tallaal (6MHP) leh ama aan lahayn CDX-1127 ee Daaweynta Heerka IIB-IV Melanoma

Tijaabadan wejiga I / II ee tijaabada ahi waxay daraasad ku samaysaa dhibaatooyinka soo raaca iyo sida wanaagsan ee tallaalku (6MHP) u leeyahay ama u leeyahay CDX-1127 inuu u shaqeeyo daaweynta heerka IIB-IV melanoma. Tallaalada, sida 6MHP, ayaa laga yaabaa inay ka caawiso jirka inuu dhiso jawaab celin wax ku ool ah oo difaac ah si loo dilo unugyada burooyinka. Immunotherapy oo leh unugyada unugyada monoclonal, sida CDX-1127, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Tijaabadan waxaa loo sameeyay si loo arko saameynta 6MHP kaligeed iyo marka lagu daro CDX-1127 ay ku leedahay isbeddelada nidaamka difaaca jirka.

Goobta: Jaamacadda Virginia Cancer Center, Charlottesville, Virginia

Ipilimumab iyo Nivolumab oo leh Immunoembolization ee Daaweynta Bukaannada qaba Metastatic Uveal Melanoma ee Beerka

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa ipilimumab iyo nivolumab oo leh tallaalka difaaca jirka ee daaweynta bukaanada qaba uveal melanoma ee ku faaftay beerka. Immunotherapy oo leh unugyada unugyada monoclonal, sida ipilimumab iyo nivolumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Immunoembolization wuxuu dili karaa unugyada burooyinka sababtoo ah luminta sahayda dhiigga iyo horumarinta jawaab celin ka dhan ah unugyada burooyinka. Ku siinta ipilimumab iyo nivolumab difaaca jirka ayaa si fiican uga shaqeyn kara daaweynta bukaanada qaba uveal melanoma.

Goobta: Isbitaalka Jaamacadda Thomas Jefferson, Philadelphia, Pennsylvania

Cyclophosphamide, Fludarabine, Tumor infiltrating Lymphocytes, iyo Aldesleukin oo lagu daaweynayo kaqeybgalayaasha Metastatic Uveal Melanoma

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa sida ugu wanaagsan ee loo yaqaan 'cyclophosphamide', 'fludarabine', buro ku soo qulqulaysa lymphocytes, iyo aldesleukin oo ka shaqeeya daaweynta ka qaybgalayaasha uveal melanoma oo ku faafay meelo kale oo jidhka ah. Daawooyinka loo isticmaalo kiimoteraabiga, sida cyclophosphamide iyo fludarabine, waxay u shaqeeyaan siyaabo kala duwan si loo joojiyo koritaanka unugyada burooyinka, iyadoo la dilayo unugyada, iyadoo laga joojinayo inay kala baxaan, ama laga joojiyo faafitaanka. Lymhocytes-ka burooyinka soo galaya ayaa laga yaabaa inay daawo wax ku ool ah u yeeshaan xuubka 'melanoma'. Aldesleukin wuxuu kicin karaa unugyada dhiigga cad si ay u dilaan unugyada 'uveal melanoma'. Bixinta cyclophosphamide, fludarabine, burooyinka soo galaya lymphocytes, iyo aldesleukin ayaa dili kara unugyo badan oo buro ah.

Goobta: Jaamacadda Pittsburgh Institute Cancer (UPCI), Pittsburgh, Pennsylvania

Autologous CD8 + SLC45A2-Specific T Lymphocytes oo leh Cyclophosphamide, Aldesleukin, iyo Ipilimumab oo lagu daaweynayo kaqeybgalayaasha Metastatic Uveal Melanoma

Tijaabadan wajiga Ib waxay daraasad ku samaynaysaa dhibaatooyinka soo raaca iyo qiyaasta ugu fiican ee iskuxidhka CD8 positive (+) SLC45A2-gaar u ah lymphocytes marka lasiiyaado cyclophosphamide, aldesleukin, iyo ipilimumab, iyo in la arko sida wanaagsan ee ay uga shaqeeyaan daaweynta kaqeybgalayaasha uveal melanoma ee ku faaftay. meelaha kale ee jirka. Si loo sameeyo unugyada CD8 + T ee khaaska ah, cilmi baarayaashu waxay kala soocaan unugyada T ee laga soo ururiyey dhiigga kaqeybgaleyaasha oo ay daaweeyaan si ay u awoodaan inay bartilmaameedsadaan unugyada melanoma. Unugyada dhiigga ayaa markaa dib loogu celinayaa ka qaybgalaha. Tan waxaa loo yaqaan "wareejinta unugga korsashada ee T" ama "korsashada T cell therapy." Daawooyinka loo isticmaalo kiimoteraabiga, sida cyclophosphamide, waxaa laga yaabaa inay u shaqeeyaan siyaabo kala duwan si loo joojiyo koritaanka unugyada burooyinka, iyadoo la dilayo unugyada, iyadoo laga joojinayo inay kala baxaan, ama la joojiyo faafitaanka. Daaweynta noolaha, sida aldesleukin, u isticmaal walxaha laga sameeyay noolaha noolaha ee kicin kara habka difaaca jirka siyaabo kala duwan una joojin kara unugyada burooyinka inay soo baxaan. Immunotherapy oo leh unugyada unugyada monoclonal, sida ipilimumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Bixinta autologous CD8 + SLC45A2-gaar ah lymphocytes oo ay weheliso cyclophosphamide, aldesleukin, iyo ipilimumab ayaa sifiican uga shaqeyn kara daaweynta kaqeybgalayaasha metastatic uveal melanoma.

Goobta: Xarunta Kansarka ee MD Anderson, Houston, Texas

Faleebada iyo Nivolumab Intrathecal ee Daaweynta Bukaannada qaba Cudurka Leptomeningeal

Marxaladani tijaabada I / Ib waxay daraasad ku samaynaysaa dhibaatooyinka soo raaca ah iyo qiyaasta ugu fiican ee intrathecal nivolumab, iyo sida ugu wanaagsan ee ay ugu shaqeyso isku darka nivolumab xididka loogu daweeyo bukaanka qaba cudurka leptomeningeal. Immunotherapy oo leh unugyada unugyada monoclonal, sida nivolumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin karaa awooda unugyada burooyinka inay koraan oo ay faafaan.

Goobta: Xarunta Kansarka ee MD Anderson, Houston, Texas

Nivolumab leh ama aan lahayn Ipilimumab ama Relatlimab kahor Qalliinka ee lagu daaweynayo Bukaannada Heerka IIIB-IV Melanoma ee laga saari karo Qalliinka

Tijaabadan wajiga labaad ee la kala soocay ayaa daraasad ku samaynaysa sida wanaagsan ee nivolumab leh ama aan lahayn ipilimumab ama relatlimab kahor qalliinka ka shaqaynta daaweynta bukaanka qaba heerka IIIB-IV melanoma oo qalliin lagaga saari karo. Immunotherapy oo leh unugyada unugyada monoclonal, sida nivolumab, ipilimumab, iyo relatlimab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragalin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Siinta nivolumab oo keli ah ama lagu daro ipilimumab ama relatlimab qalliinka ka hor ayaa laga yaabaa inay burooyinka yareyso ayna yareyso tirada unugyada caadiga ah ee loo baahan yahay in laga soo saaro.

Goobta: Xarunta Kansarka ee MD Anderson, Houston, Texas

6MHP Tallaalka iyo Ipilimumab ee lagu daaweynayo bukaanka qaba marxaladda IIA-IV Melanoma

Tijaabadan wajiga I / II waxay daraasad ku samaynaysaa dhibaatooyinka soo raaca ee 6 melanoma helper peptide tallaalka (6MHP) iyo ipilimumab iyo in la arko sida wanaagsan ee ay ugu shaqeeyaan daaweynta bukaanka qaba heerka IIA-IV melanoma. Tallaallada laga sameeyay peptides, sida tallaalka 6MHP, ayaa laga yaabaa inay ka caawiso jirka inuu dhiso jawaab celin wax ku ool ah oo difaac ah si loo dilo unugyada burooyinka. Immunotherapy oo leh unugyada unugyada monoclonal, sida ipilimumab, ayaa laga yaabaa inay ka caawiso habka difaaca jirka inuu weeraro kansarka, wuxuuna faragelin karaa awooda unugyada burooyinka inay koraan oo ay faafaan. Wali lama oga in bixinta talaalka 6MHP iyo ipilimumab ay sifiican uga shaqeeyaan daaweynta bukaanada qaba melanoma.

Goobta: Jaamacadda Virginia Cancer Center, Charlottesville, Virginia

Dabrafenib Mesylate, Trametinib, iyo 6 Melanoma Caawiyaha Tallaalka Peptide ee lagu daaweynayo bukaanka qaba marxaladda IIIB-IV Melanoma

Tijaabadan wajiga koowaad ee I / II waxay daraasad ku samaynaysaa dhibaatooyinka soo raaca iyo sida ugu wanaagsan ee dabrafenib mesylate, trametinib, iyo 6 melanoma helper peptide tallaal uga shaqeeyaan daaweynta bukaanka qaba marxaladda IIIB-IV melanoma. Dabrafenib mesylate iyo trametinib ayaa laga yaabaa inay joojiyaan koritaanka unugyada burooyinka iyagoo xannibaya qaar ka mid ah enzymes-ka loo baahan yahay koritaanka unugyada. Tallaallada, sida 6 tallaalka melanoma caawiye peptide, oo laga sameeyay peptides ka soo jeeda borotiinka melanoma, ayaa laga yaabaa inay ka caawiso jirka inuu dhiso jawaab celin wax ku ool ah si loo dilo unugyada burooyinka ee muujiya antigens-ka gaarka ah ee melanoma. Bixinta dabrafenib, trametinib, iyo 6 melanoma helper peptide tallaalka ayaa si fiican uga shaqeyn kara daaweynta bukaanada qaba melanoma.

Goobta: Jaamacadda Virginia Cancer Center, Charlottesville, Virginia

Sunitinib Malate ama Acid Valproic ee Ka Hortagga Metastasis ee Bukaannada qaba Khatarta Sare ee Uveal Melanoma

Tijaabadan wejiga labaad ee la kala soocay ayaa daraasad ku samaynaysa sida ugu wanaagsan ee sunitinib malate ama valproic acid ay u shaqayso si looga hortago uveal uveal (isha) melanoma oo ku faafta qaybaha kale ee jidhka. Sunitinib malate ayaa laga yaabaa inay joojiso gudbinta calaamadaha koritaanka unugyada burooyinka waxayna ka hortagtaa inay unugyadan koraan. Valproic acid waxay beddeli kartaa muujinta hiddo-wadaha melanoma ee uveal melanoma waxayna xakameysaa koritaanka burooyinka.

Goobta: Isbitaalka Jaamacadda Thomas Jefferson, Philadelphia, Pennsylvania

Lymphocytes-ka Burooyinka Burooyinka iyo Qiyaasta Sare Aldesleukin oo leh ama aan lahayn Unugyada 'Autologous Dendritic' ee Daaweynta Bukaannada qaba Melanoma Metastatic

Marxaladan tijaabada ah ee wajiga labaad ee la kala soocay ayaa daraasadeysa sida ugu wanaagsan ee burooyinka daweynta ee u soo galaya lymphocytes iyo qiyaasta sare ee aldesleukin oo leh ama aan lahayn unugyada dendritic autologous ay ka shaqeeyaan daaweynta bukaanada qaba melanoma ee ku faafay meelaha kale ee jirka. Tallaallada laga sameeyay unugyada burooyinka qofka iyo unugyada dhiigga ee gaarka ah (unugyada dendritic) ayaa laga yaabaa inay ka caawiyaan jirka inuu dhiso jawaab celin wax ku ool ah oo disho unugyada burooyinka. Aldesleukin wuxuu kicin karaa unugyada dhiigga cad si ay u dilaan unugyada burooyinka. Wali lama oga in burooyinka daweynta ee soo galaya lymphocytes iyo qiyaasta sare ee aldesleukin ay waxtar badan leeyihiin marka la isla qaato ama aan la helin unugyada dendritic ee yaraanaya ama gaabinaya koritaanka melanoma. Faa'iidooyinka caafimaad ee helitaanka burooyinka infakshanka 'lymphocytes' (TIL) oo ay weheliso B-Raf proto-oncogene, Kahortaga 'serine / threonine kinase (BRAF) inhibitor' ayaa la baran doonaa, bukaanada qaba cudurka horusocodka (PD) iyadoo la isticmaalayo ka hortagga BRAF kahor daaweynta TIL. Cudurka 'Leptomeningeal disease' (LMD) nasiib daro waa horumar guud oo ku dhaca bukaanada qaba melanoma, oo leh saadaal aad u liidata, oo loo tarjumay badbaado guud oo toddobaadyo ah. Iyadoo la adeegsanayo habka cusub ee la isugu darayo TIL-yada intrathecal iyo intrathecal interleukin (IL) -2, cilmi baarayaashu waxay rajeynayaan inay keenaan xasilinta cudurka muddada dheer ama cafinta LMD.

Goobta: Xarunta Kansarka ee MD Anderson, Houston, Texas

Vorinostat ee Daaweynta Fasalka 2 ee Uveal Melanoma

Marxaladan hore ee tijaabada ah waxaan daraaseynayaa sida ugu wanaagsan ee vorinostat uu ugu shaqeeyo daaweynta bukaanada leh uveal uveal uveal (eye) melanoma. Baarayaasha ayaa ogaanaya in unugyada ku jira uveal melanomas inta badan ay u qaybsan yihiin laba nooc: fasalka 1 iyo fasalka 2aad. Nooca 2 unugyada waxay u muuqdaan inay leeyihiin fursad sare oo ay ugu guuraan xubnaha kale ee jirka, halka unugyada fasalka 1 ay inta badan ku jiraan isha. Vorinostat waxaa laga yaabaa inuu awoodo inuu u beddelo unugyada heerka 2aad unugyo nooca fasalka 1-aad u yar ka xoog badan asagoo "daaraya" hidda-wadayaasha ku jira unugga xakameynaya burooyinka.

Goobta: Jaamacadda Miami Miller School of Medicine-Xarunta Kansarka ee Sylvester, Miami, Florida

Ulixertinib ee Daaweynta Bukaannada Heerka IV Uveal Melanoma

Tijaabadan wejiga II ah waxay daraasad ku samaysaa dhibaatooyinka soo raaca ee ulixertinib iyo sida ugu wanaagsan ee ay ugu shaqeyso daaweynta bukaanada qaba heerka IV uveal melanoma. Ulixertinib ayaa laga yaabaa inay joojiso koritaanka unugyada burooyinka iyagoo xayiraya qaar ka mid ah enzymes-ka loo baahan yahay koritaanka unugyada.

Goobta: Eeg Tijaabooyinka Caafimaadka Clinic.gov

Vorinostat ee Daaweynta Bukaanka ee Melanoma ee Meastada isha

Tijaabadan wejiga II ah waxay daraasad ku samaynaysaa sida wanaagsan ee vorinostat ugu shaqeeyo daaweynta bukaanka qaba melanoma ee isha oo ku faaftay qaybaha kale ee jirka. Vorinostat wuxuu joojin karaa koritaanka unugyada burooyinka isagoo xannibaya qaar ka mid ah enzymes-ka loo baahan yahay koritaanka unugyada.

Goobta: Eeg Tijaabooyinka Caafimaadka Clinic.gov